AYTU BIOPHARMA, INC Other Significant Noncash Transaction, Value of Consideration Given
AYTU BIOPHARMA, INC (AYTU) reported Other Significant Noncash Transaction, Value of Consideration Given of $0 for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1 · last filed 2026-09-22
- AYTU BIOPHARMA, INC other significant noncash transaction, value of consideration given for the quarter ending 2026-06-30 was $0.00.
- AYTU BIOPHARMA, INC other significant noncash transaction, value of consideration given for the quarter ending 2026-03-31 was $0.00.
- AYTU BIOPHARMA, INC other significant noncash transaction, value of consideration given for the quarter ending 2025-12-31 was $0.00.
- AYTU BIOPHARMA, INC other significant noncash transaction, value of consideration given for the quarter ending 2025-09-30 was $0.00, a 100.00% decline year-over-year.
- AYTU BIOPHARMA, INC other significant noncash transaction, value of consideration given for fiscal 2026 was $0.00, a 100.00% decline from fiscal 2025.
- AYTU BIOPHARMA, INC other significant noncash transaction, value of consideration given for fiscal 2025 was $483.00K, a 38.63% decline from fiscal 2024.
- AYTU BIOPHARMA, INC other significant noncash transaction, value of consideration given for fiscal 2024 was $787.00K, a 435.37% increase from fiscal 2023.
- AYTU BIOPHARMA, INC other significant noncash transaction, value of consideration given for fiscal 2023 was $147.00K, a 172.22% increase from fiscal 2022.
| Period end | Other Significant Noncash Transaction, Value of Consideration Given 3 month | Other Significant Noncash Transaction, Value of Consideration Given 6 month | Other Significant Noncash Transaction, Value of Consideration Given 9 month | Other Significant Noncash Transaction, Value of Consideration Given 12 month |
|---|---|---|---|---|
| 2026-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | $0.00 derived: sum of 2 quarters · filed 2026-09-22 | $0.00 derived: sum of 3 quarters · filed 2026-09-22 | $0.00 10-K · filed 2026-09-22 |
| 2026-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13 | $0.00 derived: sum of 2 quarters · filed 2026-05-13 | $0.00 10-Q · filed 2026-05-13 | $0.00 derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-03 | $0.00 10-Q · filed 2026-02-03 | $0.00 derived: sum of 3 quarters · filed 2026-09-22 | $0.00 derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-09-30 | $0.00 10-Q · filed 2025-11-13 | $0.00 derived: sum of 2 quarters · filed 2026-09-22 | $0.00 derived: sum of 3 quarters · filed 2026-09-22 | $0.00 derived: sum of 4 quarters · filed 2026-09-22 |
| 2025-06-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | $0.00 derived: sum of 2 quarters · filed 2026-09-22 | $0.00 derived: sum of 3 quarters · filed 2026-09-22 | $483.00K 10-K · filed 2026-09-22 |
| 2025-03-31 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13 | $0.00 derived: sum of 2 quarters · filed 2026-05-13 | $483.00K 10-Q · filed 2026-05-13 | $552.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-03 | $483.00K 10-Q · filed 2026-02-03 | $552.00K derived: sum of 3 quarters · filed 2026-02-03 | |
| 2024-09-30 | $483.00K 10-Q · filed 2025-11-13 | $552.00K derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-06-30 | $69.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | $787.00K 10-K · filed 2025-09-23 | ||
| 2024-03-31 | $718.00K 10-Q · filed 2025-05-14 | |||
| 2023-06-30 | $147.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | $147.00K 10-K · filed 2024-09-26 | ||
| 2023-03-31 | $0.00 10-Q · filed 2024-05-15 | |||
| 2022-09-30 | $146.00K 10-Q · filed 2023-11-14 | -$273.00K derived: sum of 2 quarters · filed 2023-11-14 | $171.00K derived: sum of 3 quarters · filed 2023-11-14 | $184.00K derived: sum of 4 quarters · filed 2023-11-14 |
| 2022-06-30 | -$419.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | $25.00K derived: sum of 2 quarters · filed 2023-10-12 | $38.00K derived: sum of 3 quarters · filed 2023-10-12 | $54.00K 10-K · filed 2023-10-12 |
| 2022-03-31 | $444.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11 | $457.00K derived: sum of 2 quarters · filed 2023-05-11 | $473.00K 10-Q · filed 2023-05-11 | $407.00K derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $13.00K derived: 10-Q 6 month − 10-Q/A 3 month · filed 2023-02-21 | $29.00K 10-Q · filed 2023-02-21 | -$37.00K derived: sum of 3 quarters · filed 2023-02-21 | -$14.00K derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-09-30 | $16.00K 10-Q/A · filed 2023-02-21 | -$50.00K derived: sum of 2 quarters · filed 2023-02-21 | -$27.00K derived: sum of 3 quarters · filed 2023-02-21 | -$4.00K derived: sum of 4 quarters · filed 2023-02-21 |
| 2021-06-30 | -$66.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28 | -$43.00K derived: sum of 2 quarters · filed 2022-05-16 | -$20.00K derived: sum of 3 quarters · filed 2022-05-16 | $0.00 10-K · filed 2021-09-28 |
| 2021-03-31 | $23.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-05-16 | $46.00K derived: sum of 2 quarters · filed 2022-05-16 | $66.00K 10-Q · filed 2022-05-16 | |
| 2020-12-31 | $23.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-02-14 | $43.00K 10-Q · filed 2022-02-14 | ||
| 2020-09-30 | $20.00K 10-Q · filed 2021-11-15 | |||
| 2020-06-30 | $1.61M 10-K · filed 2021-09-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |